Key Takeaways
- • GTCR-backed Corza Medical is divesting its biosurgery business unit to EQT in a transaction that includes the TachoSil product portfolio, marking a significant portfolio restructuring for the healthcare-focused private equity firm.
- • TachoSil, a hemostatic and tissue sealing product, generates improved surgical outcomes through rapid bleeding control and tissue sealing capabilities, representing a core asset in the biosurgery unit being transferred.
- • The transaction reflects EQT's continued expansion in the medical devices and surgical solutions sector, adding a established biosurgery platform to its portfolio.
- • Deal financial terms were not disclosed in available reporting as of the announcement date.
Summary
GTCR-backed Corza Medical has agreed to sell its biosurgery business unit to EQT in a strategic divestiture announced on July 7, 2026. The transaction includes the TachoSil product portfolio, a hemostatic and tissue sealing solution used across surgical settings.
TachoSil represents a clinically differentiated asset within the biosurgery segment, with established utility in achieving rapid bleeding control and tissue sealing during surgical procedures. The product portfolio's inclusion in the sale underscores the strategic value of Corza Medical's biosurgery operations and positions EQT to expand its footprint in the surgical solutions market.
The sale represents a significant portfolio activity for GTCR, which has backed Corza Medical through its operational development. For EQT, the acquisition aligns with the firm's investment thesis around healthcare infrastructure and specialized medical device platforms serving high-frequency surgical applications. Neither party disclosed specific transaction valuations or financial terms as of the announcement.
The transaction demonstrates continued consolidation activity within the surgical biosurgery market, where established product portfolios with clinical validation command strategic interest from large alternative asset managers seeking healthcare exposure. The deal is expected to close subject to customary closing conditions, though no timeline has been publicly disclosed.
TachoSil represents a clinically differentiated asset within the biosurgery segment, with established utility in achieving rapid bleeding control and tissue sealing during surgical procedures. The product portfolio's inclusion in the sale underscores the strategic value of Corza Medical's biosurgery operations and positions EQT to expand its footprint in the surgical solutions market.
The sale represents a significant portfolio activity for GTCR, which has backed Corza Medical through its operational development. For EQT, the acquisition aligns with the firm's investment thesis around healthcare infrastructure and specialized medical device platforms serving high-frequency surgical applications. Neither party disclosed specific transaction valuations or financial terms as of the announcement.
The transaction demonstrates continued consolidation activity within the surgical biosurgery market, where established product portfolios with clinical validation command strategic interest from large alternative asset managers seeking healthcare exposure. The deal is expected to close subject to customary closing conditions, though no timeline has been publicly disclosed.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.